High tumor budding stratifies breast cancer with metastatic properties

Breast Cancer Research and Treatment

Volumn 150, Issue 2, 2015, Pages 363-371

  Salhia, Bodour ^a   Trippel, Mafalda ^b   Pfaltz, Katrin ^b   Cihoric, Nikola ^b,c   Grogg, André ^b   Lädrach, Claudia ^b   Zlobec, Inti ^b   Tapia, Coya ^b,c  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Breast cancer; Metastasis; No special type; Tumor budding; Vessel invasion

Indexed keywords

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMAN; LARGE CORE NEEDLE BIOPSY; LYMPH NODE METASTASIS; MAMMARY GLAND; MIDDLE AGED; PATHOLOGY; SECONDARY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY, LARGE-CORE NEEDLE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAMMARY GLANDS, HUMAN; MIDDLE AGED;

EID: 84925440190     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3333-3     Document Type: Article

References (27)

1. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752
3. Polyak K, Hu M (2005) Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol Neoplasia 10(3):231–247
4. Sims AH, Howell A, Howell SJ, Clarke RB (2007) Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol 4(9):516–525
5. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2001) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009
6. Gokmen-Polar Y, Badve S (2012) Breast cancer prognostic markers: where are we now? MLO Med Lab Obs 44(22):24–25
7. Schnitt SJ (2010) Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 23(Suppl 2):S60–S64
8. Wessels LF, van Welsem T, Hart AA, van’t Veer LJ, Reinders MJ, Nederlof PM (2002) Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for BRCA1 tumors. Cancer Res 62:7110–7117
9. Lugli A, Karamitopoulou E, Zlobec I (2012) Tumour budding: a promising parameter in colorectal cancer. Br J Cancer 106:1713–1717
10. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97:1180–1184
11. Zlobec I, Suter G, Perren A, Lugli A (2014) A next-generation tissue microarray (ngTMA) protocol for biomarker studies. J Vis Exp 23(91):e51893
12. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne KC, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 16:2784–2795
13. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997–4013
14. Karamitopoulou E, Zlobec I, Kölzer V, Kondi-Pafiti A, Patsouris ES, Gennatas K, Lugli A (2013) Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancer. Mod Pathol 26:295–301
15. Liang F, Cao W, Wang Y, Li L, Zhang G, Wang Z (2013) The prognostic value of tumor budding in invasive breast cancer. Pathol Res Pract 209(5):269–275
16. Zlobec I, Hädrich M, Dawson H, Koelzer VH, Borner M, Mallaev M, Schnüriger B, Inderbitzin D, Lugli A (2014) Intratumoral budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br J Cancer 110(4):1008–1013
17. Landis JR, Koch CG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174
18. Guzinska-Ustymowicz K (2005) The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res 25(2B):1269–1272
19. Niwa Y, Yamada S, Koike M, Kanda M, Fujii T, Nakayama G, Sugimoto H, Nomoto S, Fujiwara M, Kodera Y (2014) Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma. J Surg Oncol 110(6):764–769
20. Karamitopoulou E, Zlobec I, Born D, Kondi-Pafiti A, Lykoudis P, Mellou A, Genatas K, Gloor B, Lugli A (2013) Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Eur J Cancer 49(5):1032–1039
21. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) (2012) WHO classification of tumours of the breast, 4the edn. IARC Press, Lyon
22. Zlobec I, Lugli A (2010) Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 1(7):651–661
23. Sun Y, Wang Y, Fan C, Gao P, Wang X, Wie G, Wie J (2014) Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Mol Cancer 3(13):137. doi:10.1186/1476-4598-13-137
24. Jiménez-Salazar JE, Posadas-Rodriquez P, Lazzarini-Lechuga RC, Luna-Lopez A, Zentella-Dehesa A, Gomez-Quiroz LE, Königsberg M, Dominquez-Gomez G, Damian-Matsumura P (2014) Membrane-initiated estradiol signaling of epithelial-mesenchymal transition-associated mechanisms through regulation of tight junctions in human breast cancer cells. Horm Cancer 5(3):161–173
25. Chen H, Shen A, Zhang Y, Chen Y, Lin J, Lin W, Sferra T, Peng J (2014) Pien Tze Huang inhibits hypoxia-induced epithelial-mesenchymal transition in human colon carcinoma cells through suppression of the HIF-1 pathway. Exp Ther Med 7(5):1237–1242
26. Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, Obermann E, Oehlschlegel C, Padberg B, Rakozy C, Sancho Oliver S, Schobinger-Clement S, Schreiber-Facklam H, Singer G, Tapia C, Wagner U, Mastropasqua MG, Viale G, Lehr AH (2012) How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss working group of breast- and gynecopathologists. PLoS One 7(5):e37379
27. Knutsvik G, Stefansson IM, Aziz S, Arnes J, Eide J, Collett K, Akslen LA (2014) Evluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One 9(11):e112121